FrancophonIA/ELRC3.0 huggingface dataset:
English: • diarrhoea that keeps getting worse or does not go away, or stools that contains blood or mucus this may happen during or after treatment is stopped with Zavicefta.
Estonian: • Süvenev või püsiv kõhulahtisus või verd või lima sisaldav väljaheide - see võib tekkida ravi ajal
English: Hepatic impairment No dosage adjustment is required in patients with hepatic impairment (see section 5.2).
Estonian: Maksapuudulikkus Maksapuudulikkusega patsientidel ei ole annuse kohandamine vajalik (vt lõik 5.2).
English: A total of 81 cUTI patients (7.4%) had bacteraemia at baseline.
Estonian: Alguses esines baktereemia kokku 81 tüsistunud kuseteede infektsiooniga patsiendil (7,4%).
English: Pseudomonas aeruginosa
Estonian: Enterobacteriaceae Pseudomonas aeruginosa
English: Efficacy has been demonstrated in clinical studies against the following pathogens that were susceptible to ceftazidime/avibactam in vitro.
Estonian: Järgmistel patogeenidel on kliinilistes uuringutes tõestatud in vitro tundlikkus tseftasidiim/avibaktaami suhtes.
English: Vomiting
Estonian: Oksendamine
English: The reconstituted solution must be further diluted to produce Zavicefta solution for infusion.
Estonian: Kontsentraati peab Zavicefta infusioonilahuse saamiseks täiendavalt lahjendama.
English: No synergy or antagonism was demonstrated in in vitro drug combination studies with ceftazidime/avibactam and metronidazole, tobramycin, levofloxacin, vancomycin, linezolid, colistin and tigecycline.
Estonian: Tseftasidiim/avibaktaami ning metronidasooli, tobramütsiini, levofloksatsiini, vankomütsiini, linesoliidi, kolistiini ja tigetsükliini in vitro koostoime uuringud ei näidanud sünergilist ega antagonistlikku toimet.
English: No appreciable accumulation of ceftazidime or avibactam was observed following multiple intravenous infusions of 2000 mg/500 mg of ceftazidime/avibactam administered every 8 hours for up to 11 days in healthy adults with normal renal function.
Estonian: Kui tervetele, normaalse neerutalitlusega täiskasvanutele manustati korduvate intravenoossete infusioonidena 2000 mg/500 mg tseftasidiim/avibaktaami iga 8 tunni järel kuni 11 päeva, ei täheldatud tseftasidiimi ega avibaktaami olulist kuhjumist.
English: Infusion site phlebitis
Estonian: Infusioonikoha flebiit
English: Ceftazidime
Estonian: Tseftasidiim
English: • Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
Estonian: • haiglatekkene kopsupõletik, sh ventilaatorpneumoonia.
English: Dosage strength ceftazidime/avibactam (mg)
Estonian: Annuse tugevus tseftasidiim/avibaktaam (mg)
English: • you have ever had a severe allergic reaction to other antibiotics belonging to the penicillin or carbapenem groups
Estonian: - kui olete teiste tsefalosporiinantibiootikumide suhtes allergiline; - kui teil on esinenud raske allergiline reaktsioon teiste penitsilliin- või karbapeneemrühma antibiootikumide suhtes.
English: Infusion site thrombosis
Estonian: Infusioonikoha tromboos
English: Complicated intra-abdominal infections Gram-negative micro-organisms
Estonian: Tüsistunud kõhuõõne infektsioonid Gram-negatiivsed mikroorganismid
English: • decrease in the number of some types of blood cells (called “leucocytes”) - shown in blood tests
Estonian: • teatud vereliblede (leukotsüüdid) arvu vähenemine vereanalüüsis;
English: Blood alkaline phosphatase increased
Estonian: Aluselise fosfataasi sisalduse suurenemine veres
English: Eosinophilia
Estonian: Eosinofiilia
English: Complicated intra-abdominal infections
Estonian: Tüsistunud kõhuõõne infektsioonid
English: ZAVICEFTA 2 g/0.5 g powder for concentrate ceftazidime/avibactam
Estonian: ZAVICEFTA 2 g/0,5 g kontsentraadi pulber ceftazidimum/avibactamum IV
English: CARTON
Estonian: KARP
English: Intravenous use
Estonian: Intravenoosne
English: • an infection of the lungs called “pneumonia”
Estonian: • kopsupõletik (pneumoonia),
English: People with kidney problems
Estonian: Neeruprobleemidega patsiendid
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 - 8ºC, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
Estonian: Ravimit võib säilitada kuni 24 tundi temperatuuril 2…8 °C, välja arvatud juhul, kui manustamiskõlblikuks muutmine on toimunud kontrollitud ja valideeritud aseptilistes tingimustes.
English: Table 1 Recommended intravenous dose for patients with estimated CrCL ≥ 51 mL/min Type of infection
Estonian: Soovituslik intravenoosne annus patsientidele, kelle hinnanguline kreatiniini kliirens on ≥ 51 ml/min
English: • diarrhoea
Estonian: • kõhulahtisus;
English: • change in the number of some types of blood cells (called “eosinophils” and “thrombocytes”)
Estonian: • teatud vereliblede (eosinofiilide ja trombotsüütide) arvu muutus vereanalüüsis;
English: Hospital-acquired pneumonia, including VAP
Estonian: Haiglatekkene kopsupõletik, sh ventilaatorpneumoonia
English: Hypersensitivity reactions
Estonian: Ülitundlikkusreaktsioonid
English: ZAVICEFTA 2 g/0.5g powder for concentrate for solution for infusion ceftazidime/avibactam
Estonian: ZAVICEFTA 2 g/0,5g infusioonilahuse kontsentraadi pulber ceftazidimum/avibactamum
English: Sodium carbonate (anhydrous)
Estonian: Veevaba naatriumkarbonaat
English: To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy There is very limited experience with the use of Zavicefta for more than 14 days
Estonian: Kasutamiseks kombinatsioonis metronidasooliga, kui on teada või kahtlustatakse, et infektsiooniprotsessis osalevad ka anaeroobsed patogeenid.
English: Nephrotoxicity
Estonian: Nefrotoksilisus
English: Agranulocytosis
Estonian: Annustamisskeem
English: • tingling or numbness
Estonian: • torkimistunne või tuimus;
English: Pyrexia
Estonian: Pearinglus
English: Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion
Estonian: Zavicefta 2 g/0,5 g infusioonilahuse kontsentraadi pulber.
English: Posology
Estonian: Lümfotsütoos
English: • headache
Estonian: • peavalu;
English: Complicated UTI, including pyelonephritis
Estonian: Tüsistunud kuseteede infektsioon, sh püelonefriit
English: shown in blood tests
Estonian: Uureasisalduse suurenemine veres
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, reproduction toxicity or genotoxicity.
Estonian: Farmakoloogilise ohutuse, korduvtoksilisuse ja genotoksilisuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: Talk to your doctor or nurse before using Zavicefta if:
Estonian: Enne Zavicefta võtmist pidage nõu oma arsti või meditsiiniõega:
English: Serious side effects
Estonian: Rasked kõrvaltoimed
English: Dose of ceftazidime/avibactam
Estonian: Tseftasidiim/ avibaktaami annus
English: • infections of the bladder or kidneys called “urinary tract infections”
Estonian: • põie või neerude (kuseteede) infektsioonid,
English: Susceptibility testing breakpoints
Estonian: Tundlikkuse testimise läviväärtused
English: Zavicefta contains sodium
Estonian: Zavicefta sisaldab naatriumi
English: • increase in the number of a type of blood cell (called “lymphocytes”) - shown in blood tests
Estonian: • teatud vereliblede (lümfotsüüdid) arvu suurenemine vereanalüüsis;
English: Dose regimen
Estonian: Kogu ruumala
English: Complicated IAI
Estonian: Väga sage Sage
English: Duration of treatment
Estonian: RAVIMI VÄLJASTAMISTINGIMUSED
English: Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Estonian: Antibakteriaalsete ravimite kasutamisel tuleb järgida kohalikke kehtivaid juhendeid.
English: Caution should be used if ceftazidime/avibactam is given to patients with a history of non-severe hypersensitivity to penicillins, monobactams or carbapenems.
Estonian: Kui patsiendil on anamneesis mitteraske ülitundlikkusreaktsioon penitsilliinide, monobaktaamide või karbapeneemide suhtes, peab tseftasidiim/avibaktaami manustamisel olema ettevaatlik.
English: Driving and using machines Zavicefta may make you feel dizzy.
Estonian: Zavicefta võib põhjustada pearinglust.
English: Dizziness
Estonian: Tundlik
English: Non-susceptible organisms
Estonian: Resistentsed mikroorganismid
English: Ceftazidime concentrations of 4 to 20 mg/L or more are achieved in the CSF when the meninges are inflamed.
Estonian: Ajukelmepõletiku korral on tseftasidiimi kontsentratsioonid seljaajuvedelikus 4…20 mg/l või enam.
English: Unchanged avibactam was the major drug-related component in human plasma and urine following dosing with [
Estonian: C]-avibaktaami manustamist inimese vereplasmas ja uriinis peamine ravimiga seotud komponent.
English: Ceftazidime and avibactam are eliminated via the kidneys, therefore, the dose should be reduced according to the degree of renal impairment (see section 4.2).
Estonian: Seetõttu peaks neerupuudulikkuse astet silmas pidades nende annust vähendama (vt lõik 4.2).
English: ANNEX II
Estonian: Tabel 2.
English: Hepatic impairment
Estonian: Tüsistunud kõhuõõne infektsioon
English: • Complicated intra-abdominal infection (cIAI)
Estonian: • reljeefne sügelev nahalööve (nõgestõbi);
English: The following indications have been justified:
Estonian: Põhjendatud on järgmised näidustused.
English: Introduction and background
Estonian: Sissejuhatus ja taust
English: Consequently, the same conclusions on efficacy and safety apply to both products.
Estonian: Seetõttu kehtivad mõlemale ravimile samad tõhusust ja ohutust käsitlevad otsused.
English: Calves and Pigs
Estonian: Vasikad ja sead
English: Strength / Active substance (INN)
Estonian: Ravimvorm Tugevus/toimeaine (INN)
English: Member State / Marketing Authorisation Number
Estonian: Liikmesriik / müügiloa number Müügiloa hoidja
English: The Netherlands (REG NL 10411)
Estonian: Madalmaad (REG NL 10411)
English: The aim of the assessment was to establish whether marketing authorisations and applications included in the referral procedure should be granted, maintained, suspended, varied or revoked with view to the grounds for referral.
Estonian: Hindamise eesmärk oli kindlaks teha, kas esildismenetluses sisalduvad müügiload ja taotlused tuleb esildise esitamise põhjuste alusel heaks kiita, säilitada, peatada, muuta või tühistada.
English: Dopharma also described the history of the product since 1987, the year of its first authorisation in the Netherlands.
Estonian: Dopharma kirjeldas ka ravimi ajalugu aastast 1987, kui ravimile anti esimest korda Madalmaades müügiluba.
English: 2.1 Questions put to the Marketing Authorisation Holder
Estonian: 2.1 Müügiloa hoidjale esitatud küsimused
English: Oral explanations were provided on 15 July 2008 and the CVMP Opinion was adopted on 16 July 2008.
Estonian: Suulised selgitused anti 15. juulil 2008 ja veterinaarravimite komitee arvamus võeti vastu 16. juulil
English: No PSURs were submitted as the product is not yet marketed.
Estonian: Perioodiliselt uuendatavaid ohutusaruandeid ei esitatud, sest ravimit veel ei turustata.
English: Coetzee et al, 2007, Journal of Veterinary Pharmacology & Therapeutics, 30, 4, 305-319.
Estonian: 1 Coetzee et al, 2007, Journal of Veterinary Pharmacology & Therapeutics, 30, 4, lk 305-319
English: The Netherlands (REG NL 8913)
Estonian: Madalmaad (REG NL 8913)
English: The Commission Decision on the Article 33 referral was adopted on 17 April 2008.
Estonian: Komisjon võttis artikli 33 alusel tehtud esildise kohase otsuse vastu 17. aprillil 2008.
English: Do not use in piglets of less than 4 weeks of age.
Estonian: Mitte kasutada alla 4-nädalastel põrsastel.
English: Pivotal documents, including the SPC, should be presented in English.
Estonian: Põhilised dokumendid, sealhulgas ravimi omaduste kokkuvõte tuleb esitada inglise keeles.
English: The Marketing Authorisation Holders and Applicant submitted written responses and the clock was restarted on 14 March 2008.
Estonian: Müügiloa hoidjad ja taotleja esitasid kirjalikud vastused ja menetlemist jätkati 14. märtsil 2008.
English: Eurovet referred to the originator product from Dopharma, Na-salicylaat 100%, REG NL 8913.
Estonian: Eurovet viitas Dopharma toodetavale originaalravimile Na-salicylaat 100%, REG NL 8913.
English: On 27 November 2007, Ireland presented to the EMEA a referral under Article 35 of Directive 2001/82/EC, as amended, concerning all oral soluble powders containing sodium salicylate which are indicated for calves and pigs.
Estonian: 27. novembril 2007 esitas Iirimaa EMEA-le muudetud direktiivi 2001/82/EÜ artikli 35 kohase esildise kõikide naatriumsalitsülaati sisaldavate suukaudsete lahustuvate pulbrite kohta, mis on näidustatud kasutamiseks vasikatel ja sigadel.
English: The clock was stopped again on 14 May 2008 and restarted on 6 June when responses to the outstanding issues where received.
Estonian: Menetlus peatati 14. mail 2008 ja jätkati 6. juunil, kui saadi vastused lahendamata küsimustele.
English: As the procedure concerns a range of products, the assessment has been limited to specific parts of the authorisations in accordance with Article 35(2) of Directive 2001/82/EC, as amended.
Estonian: Kuna menetlus puudutas mitmeid ravimeid, hinnati muudetud direktiivi 2001/82/EÜ artikli 35 lõike 2 alusel ainult lubade teatud osi.
English: ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS
Estonian: LISA III RAVIMI OMADUSTE KOKKUVÕTTE MUUDATUSED
English: ANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER / APPLICANT
Estonian: I LISA RAVIMI NIMETUS, RAVIMVORM, TUGEVUS, LOOMALIIGID, MANUSTAMISVIISID JA MÜÜGILOA HOIDJA/TAOTLEJA
English: • The benefit/risk balance of the product was shown to be positive, however in young animals, the summary of Product Characteristics should state that the product is not to be used in neonates or very young calves of less than 2 weeks of age nor in piglets of less than 4 weeks of age
Estonian: • Näidati, et ravimi kasulikkuse ja riski suhe on positiivne, kuigi noorte loomade puhul tuleb ravimi omaduste kokkuvõttes näidata, et ravim ei ole mõeldud manustamiseks vastsündinutele või väga noortele vasikatele (alla 2-nädalased) ega alla 4-nädalastele põrsastele.
English: Conclusion
Estonian: Järeldus
English: The referral procedure started on 11 December 2007 and after adoption of a list of questions, the clock was stopped on 15 January 2008.
Estonian: Esildise menetlemine algas 11. detsembril 2007. aastal ja pärast küsimuste loetelu kinnitamist peatati menetlus 15. jaanuaril 2008.
English: submitted all requested parts of the dossier (Part I and Part IV) as well as a dose determination study, which was not included in Part IV of the application dossier.
Estonian: esitas kõik palutud toimiku osad (I ja IV osa) ja samuti annuse kindlaksmääramise uuringu tulemused, mida ei olnud lisatud taotlustoimiku IV osale.
English: Ireland believed that the use of such a medicine for mass medication could mask the clinical signs of a developing infectious disease which could spread to other animals and thereby pose both an animal health and public health risk.
Estonian: Iirimaa arvas, et ravimi masskasutus võib peita arenevate nakkuste kliinilisi sümptomeid, mis võivad levida teistele loomadele ja seetõttu olla ohtlikud nii loomade kui ka rahvatervisele.
English: The dosage required for calves is however 40 mg/kg bodyweight.
Estonian: Vasikatele vajalik annus on 40 mg/kg kehakaalu kohta.
English: As a generic product only part I and not part IV of the dossier was submitted.
Estonian: Kuna tegemist on geneerilise ravimiga, esitati ainult toimiku I, mitte IV osa.
English: The MAHs are requested to provide from the dossier submitted for each country of the EEA where the products are authorised: a) the Part I Summary of the dossier including SPCs, expert reports and the full composition of the products; b) if applicable, Part IV of the application dossier; c) an Assessment of the Periodic Safety Update Reports (PSURs) in relation to target animal safety and possible lack of efficacy.
Estonian: Müügiloa hoidjatel paluti esitada väljavõtted toimikust iga Euroopa Majanduspiirkonna riigi kohta, kus ravimitel oli müügiluba: a) toimiku I osa kokkuvõte, sealhulgas ravimi omaduste kokkuvõtted, ekspertaruanded ja ravimite täielik koostis; b) võimaluse korral taotlustoimiku IV osa; c) perioodiliselt uuendatavate ohutusaruannete hinnang sihtlooma ohutuse ja võimaliku toime puudumise seisukohalt.
English: Ireland considered that there was a potentially serious risk to animal health by providing for the authorisation of a potentially ineffective medicine for mass use by farmers, especially when there are several authorised NSAIDs available for individual animal use.
Estonian: Iirimaa leidis, et potentsiaalselt ebatõhusa ravimi lubamine talunikele massiliseks kasutamiseks võib tõsiselt ohustada loomade tervist, eriti olukorras, kus saadaval on mitmeid heakskiidetud mittesteroidseid põletikuvastaseid ravimeid, mida tohib loomadele individuaalselt manustada.
English: It is known that sodium salicylate when administered by the intravenous route to calves prior to castration failed to attenuate the cortisol response1.
Estonian: On teada, et vasikatele enne kastratsiooni veenisiseselt manustatud naatriumsalitsülaat ei nõrgendanud kortisooli ravivastust1.
English: Do not use sodium salicylates in neonates or calves less than 2 weeks of age.
Estonian: Mitte kasutada naatriumsalitsülaati vastsündinud loomadel või alla 2-nädalastel vasikatel.
English: Having considered the grounds for referral and the responses provided by the Marketing Authorisation Holder and Applicant the CVMP concludes that:
Estonian: Pärast esildise põhjenduste ning müügiloa hoidja ja taotleja vastuste kaalumist järeldas veterinaarravimite komitee järgmist.
English: Dopharma submitted all requested parts of the dossier (Part I, Part IV and PSURs).
Estonian: Dopharma esitas kõik palutud toimiku osad (I ja IV osa ning perioodiliselt uuendatavad ohutusaruanded).
English: 2.2 Documentation provided
Estonian: 2.2 Esitatud dokumendid
English: It was recommended that Solacyl 100% powder for oral solution for calves and pigs should follow the outcome of the Community Referral according to Article 35(2) for sodium salicylate-containing oral soluble powders.
Estonian: Soovitati, et vasikatele ja sigadele mõeldud Solacyl 100%, suukaudse lahuse pulber peab olema kooskõlas artikli 35 lõike 2 kohaselt naatriumsalitsülaati sisaldavate suukaudsete lahustuvate pulbrite kohta tehtud ühenduse esildise tulemusega.
English: The CVMP concluded that Solacyl 100% powder for oral solution was essentially similar to the reference product, Natrium salicylaat 100%.
Estonian: Veterinaarravimite komitee leidis, et Solacyl 100% suukaudse lahuse pulber on sisuliselt samane võrdlusravimiga Natrium salicylaat 100%.
English: Solacyl was the subject of an Article 33 Referral, further to the submission of a Decentralised Application.
Estonian: Solacylile kohaldati artikli 33 alusel detsentraliseeritud esildismenetlust.
English: The MAHs should submit all existing data that could demonstrate the efficacy of sodium salicylate when given to calves and pigs, together with a thorough discussion of the these data.
Estonian: Müügiloa hoidjad peavad esitama kõik olemasolevad andmed, mis võivad tõestada vasikatele ja sigadele manustatava naatriumsalitsülaadi tõhusust koos nimetatud andmeid puudutava põhjaliku aruteluga.
English: Animal species
Estonian: Loomaliik
English: Sodium salicylate
Estonian: Naatriumsalitsülaat
English: Production, 2007; 15(3):146-151
Estonian: Paterson AR jt Journal of Swine Health and Production, 2007; 15(3), lk 146-151
English: • The efficacy of sodium salicylate as supportive treatment when given to calves and pigs was demonstrated in respiratory infections and the usefulness of this compound was clear for the treatment of inflammation in combination with concurrent antibiotic therapy.
Estonian: • Naatriumsalitsülaat oli tõhus vasikate ja sigade hingamisteede nakkuste toetava ravina ja aine kasulikkus oli selge põletiku ravis kasutatuna koos antibiootikumraviga.
English: • the use for analgesic and antipyretic effects under field condition, bearing in mind that the use in young animals which are suffering disease stress may lead to a potentiation of the undesirable effects of salicylate toxicity.
Estonian: • valuvaigistavate ja palavikku alandavate ravimite toimed välitingimustes, arvestades, et manustamine haigusest põhjustatud stressis noorloomadele võib salitsülaadi toksilisi kõrvaltoimeid tugevdada.
English: Decentralised procedure subject to an Article 33 Referral (CD 17 April 2008)
Estonian: (CD 17. aprill 2008)
English: Given this outcome together with published data on the pharmacokinetics of sodium salicylate in calves and significant variation in individual pig concentrations post treatment2, the MAHs should justify that therapeutic concentrations are established and maintained following oral use of the drug through water medication and submit all available data that could substantiate the posology and dosage regimen of sodium salicylate when given orally to calves and pigs, together with a thorough discussion of the these data.
Estonian: Arvestades seda tulemust ja avaldatud andmeid naatriumsalitsülaadi farmakokineetika kohta vasikatel ning märkimisväärset ravijärgset individuaalset ravimi sisalduse varieerumist sigadel2, peavad müügiloa hoidjad tõestama, et pärast ravimi suukaudset manustamist koos veega saavutatakse säiliv terapeutiline sisaldus.
English: Pigs: For the treatment of inflammation in combination with concurrent antibiotic therapy.
Estonian: Sead: põletike raviks koos samaaegse antibiootikumraviga.
English: Product invented name
Estonian: Ravimi nimetus
English: NA-Salicylaat, 100%, powder for solution for oral administration and NA-Salicylaat, 80% WSP
Estonian: NA-Salicylaat, 100%, lahustuv pulber suukaudseks manustamiseks ja NA-Salicylaat, 80% WSP
English: The MAHs should discuss the benefit/risk balance of the product, with special regard to:
Estonian: Müügiloa hoidjad peavad arutama ravimi kasulikkuse ja riski suhet.
English: • the merits of using sodium salicylate as an oral medication for mass administration in cattle and pigs when individual treatment with parenteral NSAIDs may offer more precise therapy;
Estonian: • vasikatele ja sigadele naatriumsalitsülaadi massilise suukaudse manustamise kasulikkus, kui individuaalne parenteraalne ravi mittesteroidse põletikuvastase ravimiga võib olla palju täpsem;
English: 4.2 Indications for use, specifying the target species Calves: supportive treatment of pyrexia in acute respiratory disease, in combination with appropriate (e.g. anti-infective) therapy if necessary.
Estonian: Vasikad: toetav palavikuravi ägeda hingamisteede haiguse esinemisel, vajadusel koos sobiva (nt nakkusevastase) raviga.
English: 4.9 Amounts to be administered and administration route In calves, the dose administered should be amended to read 40 mg/kg once daily.
Estonian: Vasikatele manustatavat annust tuleb muuta järgmiselt: 40 mg/kg üks kord ööpäevas.
English: SOLACYL 100 %, powder for oral solution for calves and pigs
Estonian: Solacyl 100 %, suukaudse lahuse pulber vasikatele ja sigadele
English: Solacyl 100 %, powder for oral solution for calves and pigs
Estonian: SOLACYL 100 %, Suukaudse lahuse pulber vasikatele ja sigadele
English: 4.2 Indications for use, specifying the target species Pigs: to promote recovery of respiration and to reduce coughing in respiratory tract infections with concurrent antibiotic therapy.
Estonian: Sead: parandab hingamise taastumist ja vähendab köha hingamisteede nakkuste puhul koos samaaegse antibiootikumraviga.
English: NA-SALICYLAAT, 100%, powder for solution for oral administration
Estonian: NA-SALICYLAAT, 100%, lahustuv pulber suukaudseks manustamiseks